Nicholas Short
M.D. Anderson Cancer Center · MD Anderson Center · MD Anderson Cancer Center, Houston, Texas
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
11
all conditions, ClinicalTrials.gov
NIH grants tied to them
1
NIH RePORTER
Trial papers
96
PubMed author-name match
Trials
Studies that name Nicholas Short as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:35 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06930651 · A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid MalignanciesM.D. Anderson Cancer Center · recruiting · Myeloid Malignancies · principal investigator
- Ph1NCT06401603 · A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06308588 · Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · recruiting · Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT06235801 · A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Myeloid Leukemia · principal investigator
- Ph2NCT05285813 · A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent FailureM.D. Anderson Cancer Center · terminated · AML, MDS · principal investigator
- Ph1/Ph2NCT05211570 · AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAB Science · recruiting · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT05032183 · Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaM.D. Anderson Cancer Center · terminated · Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT04487106 · Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome · principal investigator
- Ph2NCT04188405 · Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph1/Ph2NCT04140487 · Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmM.D. Anderson Cancer Center · recruiting · Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm · principal investigator
- Ph1/Ph2NCT03862157 · Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advancing TGFβ-Resistant CAR-NK Cell Therapy for Acute Myeloid LeukemiaR01CA315771 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $387,156 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:35 UTC. The ranking covers the 200 most relevant of 96 PubMed records, and a shared surname and initials can bring in a namesake. All 96 on PubMed
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- 220 citationsRCR 6.7
- 210 citationsRCR 6.8
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.J Clin Oncol · 2024179 citationsRCR 23.4
- 177 citationsRCR 9.5
- 171 citationsRCR 5.6
- Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.Blood · 2017153 citationsRCR 4.8
- 136 citationsRCR 4.3